Director Quantitative Pharmacology
Company | Regeneron Pharmaceuticals |
---|---|
Location | Cambridge, MA, USA, Berkeley Heights, NJ, USA, Tarrytown, NY, USA |
Salary | $202000 – $336600 |
Type | Full-Time |
Degrees | PhD |
Experience Level | Expert or higher |
Requirements
- PhD +8 years with a degree in Quantitative Pharmacology (pharmacometrics) or related field
- Hands on usage of a broad range of quantitative tools and systems is required
- Strong publication record in the field
- Excellent interpersonal and communication skills, both written and oral
- Ability to communicate complex information succinctly
- Proven experience developing QP elements of regulatory strategy and interacting with regulatory agencies without supervision
Responsibilities
- Manages and is accountable for the PK/PD evaluation of a small portfolio of products or projects
- Works independently, with guidance in only the most complex situations
- Informs PMx management of important program and regulatory developments in a timely manner
- Ensures analyses and documentation are of the highest quality and accuracy
- Ensures that reports and other documents have the appropriate messaging and that a meaningful ‘story-line’ is developed
- Ensures that study reports and other documents have an appropriate functional review and are suitable for review by senior management
- Solves complex problems; takes a broad perspective to identify solutions
- Makes contributions to multi-disciplinary meetings by sharing cross-functional skills and knowledge
Preferred Qualifications
- Fully knowledgeable of pharmacokinetic/pharmacodynamic principles, pharmacology, biology, and quantitative aspects of drug development
- Deep understanding of scientific literature and technical skills in a number of PK/PD methods and techniques
- Extensive knowledge base of the work in overall scientific community in own discipline
- Recognized as an expert in own area within the organization
- Extensive regulatory experience through authoring of regulatory briefing books, CTD summaries, contribution at HA meetings, HA negotiations through regulatory reviews and approvals of BLA or equivalent